Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service carotid revascularization cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (200 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 445 | 46% |
| 2020 | 8 | 361 | 48% |
| 2021 | 7 | 402 | 50% |
| 2022 | 9 | 351 | 53% |
| 2023 | 8 | 366 | 55% |
| 2024 | 5 | 302 | 57% |
| 2025 from claims | – | 249 202–293 | 57% |
| 2026 forecast | – | 259 203–326 | 56% |
| 2027 forecast | – | 263 195–348 | 56% |
| 2028 forecast | – | 267 189–369 | 57% |
| 2029 forecast | – | 271 184–389 | 57% |
| 2030 forecast | – | 275 180–409 | 57% |
Carotid endarterectomy and stenting including TCAR. Professional codes (what the surgeon bills): CPT 35301, 37215.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Colorado; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 46 | 2,550−2.4%/yr | −2.4%/yr | 0.7 | 0% | 2,560 in 2030+0.1%/yr |
| Arizona | 21 | 884−3%/yr | −3%/yr | 1.2 | 0% | 1,070 in 2030+3.3%/yr |
| Washington | 15 | 658−6.5%/yr | −6.5%/yr | 0.8 | 0% | 680 in 2030+0.6%/yr |
| Oregon | 8 | 425−4.9%/yr | −4.9%/yr | 1.0 | 0% | 460 in 2030+1.4%/yr |
| Nevada | 11 | 315−0.4%/yr | −0.4%/yr | 1.1 | 0% | 610 in 2030+11%/yr |
| Idaho | 7 | 243+15%/yr | +15%/yr | 1.2 | 0% | 590 in 2030+16%/yr |
| Utah | 2 | 170−2.8%/yr | −2.8%/yr | 0.8 | 0% | 110 in 2030−6.4%/yr |
| Montana | 4 | 162−1.2%/yr | −1.2%/yr | 0.8 | 0% | 170 in 2030+1.3%/yr |
| New Mexico | 1 | 111−8.3%/yr | −8.3%/yr | 0.5 | 0% | 150 in 2030+5.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 41 | 3,790+0.3%/yr | +0.3%/yr | 7.41.3× | 99% | 5,330 in 2030+5.9%/yr |
| Dialysis access | 23 | 1,386−15%/yr | −15%/yr | 3.00.6× | 39% | 1,300 in 2030−1.1%/yr |
| Peripheral arterial intervention | 6 | 1,107−8.7%/yr | −8.7%/yr | 2.20.4× | 43% | 1,830 in 2030+8.7%/yr |
| Thrombectomy, IVC filters & venous stents | 4 | 635+0.4%/yr | +0.4%/yr | 1.31.1× | 18% | 790 in 2030+3.6%/yr |
| Aortic endografts (EVAR/TEVAR) | 0 | 174−6.8%/yr | −6.8%/yr | 0.41.1× | 0% | 200 in 2030+2.7%/yr |
Carotid revascularization in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Microvention leads with 48% of company spending on these surgeons in 2025, +39 pts on 2024.
In 2025, 4 companies reported engagement with Colorado’s surgeons worth $2,503 in consulting, speaking, meals and travel tied to these products, about $501 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 19 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.